UA105503C2 - Похідні 1-аміно-2-циклобутилетилборонової кислоти - Google Patents

Похідні 1-аміно-2-циклобутилетилборонової кислоти

Info

Publication number
UA105503C2
UA105503C2 UAA201105450A UAA201105450A UA105503C2 UA 105503 C2 UA105503 C2 UA 105503C2 UA A201105450 A UAA201105450 A UA A201105450A UA A201105450 A UAA201105450 A UA A201105450A UA 105503 C2 UA105503 C2 UA 105503C2
Authority
UA
Ukraine
Prior art keywords
derivatives
amino
cyclobutylethylboronic
acid
cyclobutylethylboronic acid
Prior art date
Application number
UAA201105450A
Other languages
English (en)
Russian (ru)
Inventor
Пол Е. Флемінг
Цзин Лі
Original Assignee
Мілленніум Фармасьютікалз, Інк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мілленніум Фармасьютікалз, Інк. filed Critical Мілленніум Фармасьютікалз, Інк.
Publication of UA105503C2 publication Critical patent/UA105503C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)

Abstract

У даному винаході пропонуються сполуки, придатні як інгібітори протеасом.У винаході також пропонуються фармацевтичні композиції, що містять сполуки за винаходом, і способи застосування композицій в лікуванні різноманітних захворювань.
UAA201105450A 2008-09-29 2009-09-25 Похідні 1-аміно-2-циклобутилетилборонової кислоти UA105503C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19461408P 2008-09-29 2008-09-29
PCT/US2009/005324 WO2010036357A1 (en) 2008-09-29 2009-09-25 Derivatives of 1-amino-2-cyclobutylethylboronic acid

Publications (1)

Publication Number Publication Date
UA105503C2 true UA105503C2 (uk) 2014-05-26

Family

ID=41426361

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201105450A UA105503C2 (uk) 2008-09-29 2009-09-25 Похідні 1-аміно-2-циклобутилетилборонової кислоти

Country Status (25)

Country Link
US (3) US8664200B2 (uk)
EP (1) EP2346882B1 (uk)
JP (3) JP5736314B2 (uk)
KR (1) KR101739470B1 (uk)
CN (2) CN102203103A (uk)
AR (1) AR075090A1 (uk)
AU (1) AU2009297113B2 (uk)
BR (1) BRPI0919447B8 (uk)
CA (1) CA2739375C (uk)
CL (1) CL2011000653A1 (uk)
CO (1) CO6362015A2 (uk)
CR (2) CR20160475A (uk)
DO (1) DOP2011000086A (uk)
EA (1) EA030539B1 (uk)
EC (1) ECSP11011011A (uk)
IL (1) IL211983A0 (uk)
MA (1) MA32729B1 (uk)
MX (1) MX2011003317A (uk)
MY (1) MY166653A (uk)
NZ (2) NZ606001A (uk)
SG (1) SG194388A1 (uk)
TW (2) TW201024313A (uk)
UA (1) UA105503C2 (uk)
WO (1) WO2010036357A1 (uk)
ZA (1) ZA201203615B (uk)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY171061A (en) 2005-11-09 2019-09-24 Onyx Therapeutics Inc Compounds for enzyme inhibition
CA2657213C (en) 2006-06-19 2017-01-03 Proteolix, Inc. Peptide epoxyketones for proteasome inhibition
KR20170125413A (ko) 2007-10-04 2017-11-14 오닉스 세라퓨틱스, 인크. 결정형 펩티드 에폭시 케톤 프로테아제 저해제 및 아미노산 케토-에폭시드의 합성
EP2730579A1 (en) 2008-06-17 2014-05-14 Millennium Pharmaceuticals, Inc. Boronate ester compounds and pharmaceutical compositions thereof
EP3090737A1 (en) 2008-10-21 2016-11-09 Onyx Therapeutics, Inc. Combination therapy with peptide epoxyketones
TWI504598B (zh) 2009-03-20 2015-10-21 Onyx Therapeutics Inc 結晶性三肽環氧酮蛋白酶抑制劑
US8853147B2 (en) 2009-11-13 2014-10-07 Onyx Therapeutics, Inc. Use of peptide epoxyketones for metastasis suppression
EP2542238B1 (en) * 2010-03-01 2015-08-12 Onyx Therapeutics, Inc. Compounds for immunoproteasome inhibition
MX2012011298A (es) 2010-03-31 2012-11-06 Millennium Pharm Inc Derivados del acido 1-amino-2-ciclopropiletilboronico.
CN104126017A (zh) 2011-11-11 2014-10-29 米伦纽姆医药公司 对蛋白酶体抑制剂的反应的生物标记
CN104039328B (zh) 2011-11-11 2018-10-09 米伦纽姆医药公司 对蛋白酶体抑制剂的反应的生物标记
SG11201403254QA (en) * 2011-12-22 2014-07-30 Ares Trading Sa Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors
CA2862492A1 (en) 2012-01-24 2013-08-01 Millennium Pharmaceuticals, Inc. Methods of treatment of cancer
US20140105921A1 (en) 2012-07-09 2014-04-17 Onyx Therapeutics, Inc. Prodrugs of Peptide Epoxy Ketone Protease Inhibitors
MX2015006715A (es) * 2012-12-03 2015-08-14 Hoffmann La Roche Compuestos de acido triazolboronico sustituido.
US20160250238A1 (en) 2013-10-03 2016-09-01 Millennium Pharmaceuticals, Inc. Method for the Prophylaxis or Treatment of Systemic Lupus Erythematosus and/or Lupus Nephritis
EP3092244B1 (en) 2014-01-10 2019-08-14 Cornell University Dipeptides as inhibitors of human immunoproteasomes
MA39964A (fr) 2014-05-20 2015-11-26 Millennium Pharm Inc Inhibiteurs du protéasome contenant du bore destinés à être utilisés après une thérapie contre le cancer primaire
WO2016022955A1 (en) 2014-08-07 2016-02-11 Mayo Foundation For Medical Education And Research Compounds and methods for treating cancer
CN107073069B (zh) 2014-08-18 2022-03-08 康奈尔大学 作为人免疫蛋白酶体的抑制剂的二肽模拟物
US10294246B2 (en) * 2014-10-01 2019-05-21 Merck Patent Gmbh Substituted boronic acids and boronate esters as immunoproteasome inhibitors
EP3201205B1 (en) * 2014-10-01 2020-05-13 Merck Patent GmbH Boronic acid derivatives
EP3201208B1 (en) * 2014-10-01 2021-03-24 Merck Patent GmbH Boronic acid derivatives
CN107001391B (zh) * 2014-10-01 2020-11-27 默克专利股份公司 硼酸衍生物
WO2017066763A1 (en) 2015-10-15 2017-04-20 Cornell University Proteasome inhibitors and uses thereof
US10526315B2 (en) 2016-06-21 2020-01-07 Orion Ophthalmology LLC Carbocyclic prolinamide derivatives
PL3472149T3 (pl) 2016-06-21 2024-02-12 Orion Ophthalmology LLC Heterocykliczne pochodne prolinamidu
EP4606431A3 (en) 2017-02-28 2025-11-19 Mayo Foundation for Medical Education and Research Compounds and methods for treating cancer
US11203613B2 (en) 2017-10-11 2021-12-21 Cornell University Peptidomimetic proteasome inhibitors
US11243207B2 (en) 2018-03-29 2022-02-08 Mayo Foundation For Medical Education And Research Assessing and treating cancer
ES2960987T3 (es) 2019-04-12 2024-03-07 Riboscience Llc Derivados de heteroarilo bicíclicos como inhibidores de la ectonucleótido pirofosfatasa fosfodiesterasa 1

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ203706A (en) 1982-04-22 1986-03-14 Squibb & Sons Inc Occlusive multi-layer wound dressing and hydrocolloidal granules for wound treatment
US4499082A (en) * 1983-12-05 1985-02-12 E. I. Du Pont De Nemours And Company α-Aminoboronic acid peptides
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
US5250720A (en) 1987-06-05 1993-10-05 The Dupont Merck Pharmaceutical Company Intermediates for preparing peptide boronic acid inhibitors of trypsin-like proteases
US5242904A (en) 1987-06-05 1993-09-07 The Dupont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
EP0315574A3 (de) * 1987-11-05 1990-08-22 Hoechst Aktiengesellschaft Renin-Inhibitoren
US5106948A (en) 1988-05-27 1992-04-21 Mao Foundation For Medical Education And Research Cytotoxic boronic acid peptide analogs
US5159060A (en) 1988-05-27 1992-10-27 Mayo Foundation For Medical Education And Research Cytotoxic boronic acid peptide analogs
DE3827340A1 (de) * 1988-08-12 1990-02-15 Hoechst Ag Verwendung von (alpha)-aminoboronsaeure-derivaten zur prophylaxe und behandlung von viruserkrankungen
EP0583536B1 (en) 1992-08-14 1997-03-05 The Procter & Gamble Company Liquid detergents containing an alpha-amino boronic acid
US5935944A (en) 1993-09-10 1999-08-10 Neutron Technology Corporation Formulation for I.V. administration of the boron delivery drug, boronophenylalanine (BPA)
US5492900A (en) 1993-09-10 1996-02-20 Neutron Technology Corporation Method for enhancing the solubility of the boron delivery drug, boronophenylalanine (BPA)
US6060462A (en) 1993-10-20 2000-05-09 Dupont Pharmaceuticals Company Electrophilic peptide analogs as inhibitors of trypsin-like enzymes
US5574017A (en) 1994-07-05 1996-11-12 Gutheil; William G. Antibacterial agents
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US5614649A (en) 1994-11-14 1997-03-25 Cephalon, Inc. Multicatalytic protease inhibitors
US6271199B2 (en) 1997-02-15 2001-08-07 Millennium Pharmaceuticals, Inc. Treatment of infarcts
WO1999015183A1 (en) 1997-09-25 1999-04-01 Proscript Inc. PROTEASOME INHIBITORS, UBIQUITIN PATHWAY INHIBITORS OR AGENTS THAT INTERFERE WITH THE ACTIVATION OF NF-λB VIA THE UBIQUITIN PROTEASOME PATHWAY TO TREAT INFLAMMATORY AND AUTOIMMUNE DISEASES
CA2314259A1 (en) 1997-12-16 1999-06-24 Robert Siman Multicatalytic protease inhibitors for use as anti-tumor agents
US6169076B1 (en) 1999-03-31 2001-01-02 Glcosyn Pharmaceuticals, Inc. P-Boronophenylalanine complexes with fructose and related carbohydrates and polyols
AU5920400A (en) 1999-07-07 2001-01-22 Du Pont Pharmaceuticals Company Cell-based assay systems for examining hcv ns3 protease activity
US6846806B2 (en) * 2000-10-23 2005-01-25 Bristol-Myers Squibb Company Peptide inhibitors of Hepatitis C virus NS3 protein
ES2571219T3 (es) 2001-01-25 2024-09-23 The United States Of America Represented By The Sec Dep Of Health And Human Services Formulación de compuestos de ácido borónico
WO2002096933A1 (en) 2001-05-30 2002-12-05 Novartis Ag 2-{[n-(2-amino-3-(heteroaryl or aryl)propionyl)-aminoacyl]-amino}-alkylboronic acid derivatives
JPWO2003033507A1 (ja) 2001-10-12 2005-02-03 杏林製薬株式会社 ベンジルマロン酸誘導体およびそれを含有するプロテアソーム阻害薬
AU2003219652A1 (en) 2002-01-08 2003-07-30 Eisai Co. Ltd. Eponemycin and epoxomicin analogs and uses thereof
AU2003223930A1 (en) 2002-06-14 2003-12-31 Novo Nordisk A/S Pharmaceutical use of boronic acids and esters thereof
US20060084592A1 (en) * 2002-09-09 2006-04-20 Trigen Limited Peptide boronic acid inhibitors
TW200418791A (en) 2003-01-23 2004-10-01 Bristol Myers Squibb Co Pharmaceutical compositions for inhibiting proteasome
US7576206B2 (en) * 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
UA88771C2 (uk) * 2003-08-14 2009-11-25 Сефалон, Инк. Інгібітори протеасоми та спосіб їх застосування (варіанти)
US7223745B2 (en) 2003-08-14 2007-05-29 Cephalon, Inc. Proteasome inhibitors and methods of using the same
GB0405267D0 (en) 2004-03-09 2004-04-21 Trigen Ltd Compounds
ME01975B (me) 2004-03-30 2015-05-20 Millennium Pharm Inc Sinteza jedinjenja estra organoborne kiseline i organoborne kiseline
US7468383B2 (en) 2005-02-11 2008-12-23 Cephalon, Inc. Proteasome inhibitors and methods of using the same
US7998997B2 (en) 2005-07-05 2011-08-16 Trustees Of Tufts College Inhibitors of fibroblast activation protein alpha
EP2029153A2 (en) 2006-01-27 2009-03-04 Phenomix Corporation Hepatitis c serine protease inhibitors and uses therefor
WO2009006473A2 (en) 2007-07-05 2009-01-08 Trustees Of Tufts College Pro-soft polypeptide proteasome inhibitors, and methods of use thereof
PL2178888T3 (pl) 2007-08-06 2012-11-30 Millennium Pharm Inc Inhibitory proteasomów
US7442830B1 (en) 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
EP2730579A1 (en) 2008-06-17 2014-05-14 Millennium Pharmaceuticals, Inc. Boronate ester compounds and pharmaceutical compositions thereof
MX2012011298A (es) 2010-03-31 2012-11-06 Millennium Pharm Inc Derivados del acido 1-amino-2-ciclopropiletilboronico.

Also Published As

Publication number Publication date
JP5736314B2 (ja) 2015-06-17
KR20110082534A (ko) 2011-07-19
US20170349611A1 (en) 2017-12-07
TW201641504A (zh) 2016-12-01
US20100081633A1 (en) 2010-04-01
NZ606001A (en) 2014-08-29
US9771381B2 (en) 2017-09-26
CL2011000653A1 (es) 2011-09-30
MA32729B1 (fr) 2011-10-02
US8664200B2 (en) 2014-03-04
EP2346882B1 (en) 2017-09-20
CA2739375A1 (en) 2010-04-01
NZ592497A (en) 2013-02-22
TW201024313A (en) 2010-07-01
US10035811B2 (en) 2018-07-31
ECSP11011011A (es) 2011-07-29
MX2011003317A (es) 2011-04-26
CN103554143B (zh) 2018-02-23
CN102203103A (zh) 2011-09-28
SG194388A1 (en) 2013-11-29
CA2739375C (en) 2019-03-12
AR075090A1 (es) 2011-03-09
JP2012504122A (ja) 2012-02-16
ZA201203615B (en) 2015-03-25
AU2009297113B2 (en) 2016-11-10
CR20110216A (es) 2011-07-14
IL211983A0 (en) 2011-06-30
TWI598352B (zh) 2017-09-11
EP2346882A1 (en) 2011-07-27
JP2015143264A (ja) 2015-08-06
KR101739470B1 (ko) 2017-05-24
BRPI0919447B8 (pt) 2021-05-25
EA201170508A1 (ru) 2011-10-31
MY166653A (en) 2018-07-18
CN103554143A (zh) 2014-02-05
EA030539B1 (ru) 2018-08-31
DOP2011000086A (es) 2011-04-15
BRPI0919447A2 (pt) 2015-12-15
BRPI0919447B1 (pt) 2021-03-30
CO6362015A2 (es) 2012-01-20
JP2017025091A (ja) 2017-02-02
CR20160475A (es) 2016-12-19
WO2010036357A1 (en) 2010-04-01
AU2009297113A1 (en) 2010-04-01
US20140194387A1 (en) 2014-07-10

Similar Documents

Publication Publication Date Title
MY166653A (en) Derivatives of 1-amino-2-cyclobutylethylboronic acid
TN2012000465A1 (en) Derivatives of 1-amino-2-cyclopropylethylboronic acid
PH12014500053A1 (en) Proteasome inhibitors
PH12015501192A1 (en) Boronate ester compounds and pharmaceutical compositions thereof
CA2818187C (en) Bromodomain inhibitors and uses thereof
IN2012DN00971A (uk)
TN2010000203A1 (en) Beta-lactamase inhibitors
CA2871471C (en) Dna-pk inhibitors
MX2009006706A (es) Compuestos heterociclicos biciclicos como inhibidores del receptor del factor de crecimiento de fibroblastos.
MY163275A (en) Ibat inhibitors for the treatment of liver diseases
MA33803B1 (fr) Inhibiteur de bromodomaine de benzodiazépine
JO3007B1 (ar) مركبات و تركيبات كمثبطات كيناز بروتين
EA201170832A1 (ru) Пуриновые соединения
MX2011006006A (es) Compuestos, composicion farmaceutica y metodos para utilizarse en el tratamiento de trastornos metabolicos.
MX2011013032A (es) Inhibidores de fosfatidilinositol 3-cinasa.
ZA201003352B (en) Heterocyclic derivatives as modulators of ion channels
MX2011008645A (es) Inhibidores de tetrahidrotiazolopiridina de fosfatidilinositol 3 cinasa.
MY180594A (en) Proteasome inhibitors
UA106205C2 (uk) Сполуки боронатного ефіру, фармацевтична композиція (варіанти), яка містить їх, і спосіб їх одержання (варіанти)
EA201791835A2 (ru) Ингибиторы протеасом